Comparison of the 2022 world health organization classification and international consensus classification in myelodysplastic syndromes/neoplasms.

ABSTRACT: In 2022, two novel classification systems for myelodysplastic syndromes/neoplasms (MDS) have been proposed: the International Consensus Classification (ICC) and the 2022 World Health Organization (WHO-2022) classification. These two contemporary systems exhibit numerous shared features but also diverge significantly in terminology and the definition of new entities. Thus, we retrospectively validated the ICC and WHO-2022 classification and found that both systems promoted efficient segregation of this heterogeneous disease. After examining the distinction between the two systems, we showed that a peripheral blood blast percentage ≥ 5% indicates adverse survival. Identifying MDS/acute myeloid leukemia with MDS-related gene mutations or cytogenetic abnormalities helps differentiate survival

SUBMITTER: Lee WH 

PROVIDER: S-EPMC11004131 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature